ES2558330T3 - Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo - Google Patents

Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo Download PDF

Info

Publication number
ES2558330T3
ES2558330T3 ES12174393.4T ES12174393T ES2558330T3 ES 2558330 T3 ES2558330 T3 ES 2558330T3 ES 12174393 T ES12174393 T ES 12174393T ES 2558330 T3 ES2558330 T3 ES 2558330T3
Authority
ES
Spain
Prior art keywords
amino acid
peptide
hla
restricted
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12174393.4T
Other languages
English (en)
Inventor
Haruo Sugiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Institute of Cancer Immunology Inc
Original Assignee
International Institute of Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Institute of Cancer Immunology Inc filed Critical International Institute of Cancer Immunology Inc
Application granted granted Critical
Publication of ES2558330T3 publication Critical patent/ES2558330T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)

Abstract

Un péptido constituido por la secuencia de aminoácidos de Ser Asp Gln Leu Lys Arg His Gln Arg (SEC ID N.º: 4) donde un aminoácido está sustituido por otro aminoácido, donde el aminoácido en la posición 2 se selecciona de Ala, Ile, Leu, Val, Phe, Tyr, Ser y Asp, y el aminoácido en la posición 9 es Arg, donde dicho péptido tiene una capacidad para unirse a una molécula de HLA-A*3303 y una capacidad para inducir un CTL.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
ES12174393.4T 2006-02-22 2007-02-21 Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo Active ES2558330T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006045287 2006-02-22
JP2006045287 2006-02-22

Publications (1)

Publication Number Publication Date
ES2558330T3 true ES2558330T3 (es) 2016-02-03

Family

ID=38437397

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11161436.8T Active ES2587980T3 (es) 2006-02-22 2007-02-21 Péptido WT1 con restricción HLA-A*3303 y composición farmacéutica que lo contiene
ES07714676T Active ES2387685T3 (es) 2006-02-22 2007-02-21 Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
ES12174393.4T Active ES2558330T3 (es) 2006-02-22 2007-02-21 Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES11161436.8T Active ES2587980T3 (es) 2006-02-22 2007-02-21 Péptido WT1 con restricción HLA-A*3303 y composición farmacéutica que lo contiene
ES07714676T Active ES2387685T3 (es) 2006-02-22 2007-02-21 Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo

Country Status (22)

Country Link
US (5) US8759483B2 (es)
EP (3) EP2385117B1 (es)
JP (1) JP5393144B2 (es)
KR (1) KR101391561B1 (es)
CN (3) CN102250211A (es)
AU (1) AU2007218649B2 (es)
BR (1) BRPI0708125A2 (es)
CA (4) CA2886615A1 (es)
CY (1) CY1113117T1 (es)
DK (2) DK1988163T3 (es)
ES (3) ES2587980T3 (es)
IL (4) IL193026A (es)
MX (1) MX2008010842A (es)
MY (1) MY149527A (es)
NO (1) NO20084008L (es)
PH (1) PH12012502372A1 (es)
PL (1) PL1988163T3 (es)
PT (1) PT1988163E (es)
RU (2) RU2435782C2 (es)
SI (1) SI1988163T1 (es)
WO (1) WO2007097358A1 (es)
ZA (1) ZA200806542B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101580538B (zh) 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
PL1988163T3 (pl) 2006-02-22 2012-11-30 Int Inst Cancer Immunology Inc Ograniczony do hla-a*3303 peptyd wt1 i zawierająca go kompozycja farmaceutyczna
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
BRPI0808084A2 (pt) 2007-02-27 2014-07-22 Int Inst Cancer Immunology Inc Método para ativação de células t auxiliadoras e composição para uso no método.
EP2626418B8 (en) 2010-10-05 2021-03-24 International Institute of Cancer Immunology, Inc. Method for activating helper t cell
PH12013502043A1 (en) 2011-04-01 2013-12-16 Memorial Sloan Kettering Cancer Center T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
AU2012309417B2 (en) * 2011-09-14 2017-09-14 International Institute Of Cancer Immunology, Inc. Method for measuring anti-WT1 antibody
HK1204261A1 (en) 2012-01-13 2015-11-13 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
CN104797711B (zh) 2012-09-12 2018-09-21 株式会社癌免疫研究所 抗原特异性辅助性t细胞受体基因
CN104812401B (zh) 2012-12-13 2017-10-13 宾夕法尼亚大学理事会 Wt1疫苗
CA2892660C (en) 2012-12-17 2022-02-15 Otsuka Pharmaceutical Co., Ltd. Method for activating helper t cell
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
IN2014CH00395A (es) 2013-02-05 2015-04-03 Nitto Denko Corp
RU2685933C2 (ru) 2013-02-05 2019-04-23 Нитто Денко Корпорейшн Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения
US20140220056A1 (en) 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal administration
JP2014169275A (ja) 2013-02-05 2014-09-18 Nitto Denko Corp 粘膜投与用ワクチン組成物
EP2762156A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
CN103961702B (zh) 2013-02-05 2019-04-09 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
CN103961307B (zh) 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
CA2840959A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition
KR102797324B1 (ko) * 2014-12-11 2025-04-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 혈관 신생병의 면역 요법
CN107427581A (zh) 2014-12-25 2017-12-01 株式会社癌免疫研究所 T细胞群的改变方法
WO2016154071A1 (en) 2015-03-20 2016-09-29 The Trustees Of The University Of Isg15 and its use as an adjuvant
ES2946188T3 (es) 2016-11-09 2023-07-13 Univ Osaka Procedimiento para modificar una población de linfocitos T

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007509A1 (en) 1989-11-13 1991-05-30 Massachusetts Institute Of Technology Localization and characterization of the wilms's tumor gene
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
US6270777B1 (en) 1996-12-20 2001-08-07 University Technologies International Inc. Conserved metalloprotease epitopes
GB9805877D0 (en) * 1998-03-20 1998-05-13 Imp Cancer Res Tech Cancer
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
PL201881B1 (pl) 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
AU7859900A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US6797695B1 (en) * 1999-10-22 2004-09-28 Kyoto University Human FGF-20 gene and gene expression products
AU2001285018A1 (en) 2000-08-17 2002-02-25 Agensys, Inc. Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer
BRPI0208183B8 (pt) * 2001-03-22 2021-05-25 Sugiyama Haruo peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
US20040197892A1 (en) * 2001-04-04 2004-10-07 Michael Moore Composition binding polypeptides
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
KR101050703B1 (ko) 2002-06-12 2011-07-20 추가이 세이야쿠 가부시키가이샤 Ｈｌａ-ａ24-구속성 암 항원 펩티드
ES2538486T3 (es) * 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
US20060217297A1 (en) 2003-01-15 2006-09-28 Haruo Sugiyama Dimerized peptide
EP1590437A4 (en) 2003-01-24 2008-06-18 Agensys Inc NUCLEIC ACIDS SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER AND CORRESPONDING PROTEINS NAMED 254P1D6B
US6980709B2 (en) 2003-06-20 2005-12-27 Northrop Grumman Corporation Polymeric material with voids that compress to allow the polymeric material to absorb applied force and decrease reaction force to one or more sensor fibers
ES2556232T3 (es) 2004-03-31 2016-01-14 International Institute Of Cancer Immunology, Inc. Péptidos antigénicos del cáncer derivados de WT1
PL1988163T3 (pl) 2006-02-22 2012-11-30 Int Inst Cancer Immunology Inc Ograniczony do hla-a*3303 peptyd wt1 i zawierająca go kompozycja farmaceutyczna

Also Published As

Publication number Publication date
EP1988163B1 (en) 2012-06-27
CN101384716B (zh) 2013-03-13
US20140199332A1 (en) 2014-07-17
CA2886551A1 (en) 2007-08-30
EP2385117A1 (en) 2011-11-09
EP2385117B1 (en) 2016-07-27
CA2886552A1 (en) 2007-08-30
BRPI0708125A2 (pt) 2011-05-17
US20100292160A1 (en) 2010-11-18
EP2518149B1 (en) 2015-12-16
KR101391561B1 (ko) 2014-05-02
CN102702319B (zh) 2015-01-28
US8968745B2 (en) 2015-03-03
CY1113117T1 (el) 2016-04-13
WO2007097358A1 (ja) 2007-08-30
EP1988163A1 (en) 2008-11-05
AU2007218649B2 (en) 2013-01-10
CN102702319A (zh) 2012-10-03
US20140193443A1 (en) 2014-07-10
US8759483B2 (en) 2014-06-24
KR20080097203A (ko) 2008-11-04
RU2435782C2 (ru) 2011-12-10
US8945578B2 (en) 2015-02-03
ES2587980T3 (es) 2016-10-28
IL232409A0 (en) 2014-06-30
EP2518149A1 (en) 2012-10-31
CN101384716A (zh) 2009-03-11
EP1988163A4 (en) 2010-03-17
DK2518149T3 (en) 2016-01-11
IL218172A0 (en) 2012-03-29
ZA200806542B (en) 2009-07-29
MY149527A (en) 2013-09-13
DK1988163T3 (da) 2012-08-20
CA2886615A1 (en) 2007-08-30
MX2008010842A (es) 2008-09-01
HK1125968A1 (en) 2009-08-21
RU2011132212A (ru) 2013-02-10
SI1988163T1 (sl) 2012-09-28
RU2008137635A (ru) 2010-03-27
US20120195918A1 (en) 2012-08-02
IL232408A0 (en) 2014-06-30
US20140193442A1 (en) 2014-07-10
ES2387685T3 (es) 2012-09-28
JP5393144B2 (ja) 2014-01-22
AU2007218649A1 (en) 2007-08-30
NO20084008L (no) 2008-11-24
US8778350B2 (en) 2014-07-15
CA2638122A1 (en) 2007-08-30
PT1988163E (pt) 2012-08-28
CN102250211A (zh) 2011-11-23
IL193026A (en) 2015-09-24
PH12012502372B1 (en) 2016-04-04
US8933038B2 (en) 2015-01-13
IL193026A0 (en) 2009-02-11
PL1988163T3 (pl) 2012-11-30
PH12012502372A1 (en) 2016-04-04
JPWO2007097358A1 (ja) 2009-07-16

Similar Documents

Publication Publication Date Title
ES2558330T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
ES2559062T3 (es) Método para la activación de linfocitos T colaboradores y composición para su uso en el método
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2486675T3 (es) Análogo de péptido de oxintomodulina
PE20210376A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
ES2539812T3 (es) Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos
NO20092774L (no) HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette
PE20240595A1 (es) Inhibidores peptidicos lipidicos del receptor de iinterleucina-23
PE20140159A1 (es) Coagonistas del receptor de glucagon/glp-1
PE20090932A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1
AR050353A1 (es) Composicion de anticuerpo her2
PE20171325A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
AR076349A1 (es) Peptido auxiliar del antigeno del cancer
AR072159A1 (es) Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad
CR9452A (es) Agentes terapeuticos a base de peptidos de toxinas
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
UA103882C2 (uk) Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина
PE20120021A1 (es) Mutantes fgf21
PE20190743A1 (es) Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib
CL2020003292A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
ES2545614T3 (es) Proteínas truncadas con nudo de cistina